Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 12
Submit an article Journal homepage
141
Views
5
CrossRef citations to date
0
Altmetric
Review

Stroke prevention in the high-risk patient

J David Spence Robarts Research Institute, Stroke Prevention & Atherosclerosis Research Centre, 1400 Western Road, London, ON, N6G 2V2, Canada +1 519 663 3113; +1 519 663 3018; [email protected]
, MD
Pages 1851-1859 | Published online: 14 Aug 2007

Bibliography

  • THOM T, HAASE N, ROSAMOND W et al.:Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 113(6):E85-E151.
  • ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet (2005) 366(9499):1773-1783.
  • GORELICK PB: Stroke prevention. Arch. Neurol. (1995) 52(4):347-355.
  • HACKAM DG, SPENCE JD: Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke (2007) 38(6):1881-1885.
  • YUSUF S: Two decades of progress in preventing vascular disease. Lancet (2002) 360(9326):2-3.
  • ROTHWELL PM, WARLOW CP: Timing of TIAs preceding stroke: time window for prevention is very short. Neurology (2005) 64(5):817-820.
  • WILLETT WC, STAMPFER MJ: Rebuilding the food pyramid. Sci. Am. (2003) 288(1):64-71.
  • LICHTENSTEIN AH, APPEL LJ, BRANDS M et al.: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation (2006) 114(1):82-96.
  • GOLDSTEIN LB, ADAMS R, ALBERTS MJ et al.: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke (2006) (6):1583-1633.
  • SACKS FM, SVETKEY LP, VOLLMER WM et al.: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. (2001) 344(1):3-10.
  • DE LOEGERIL M, RENAUD S, MAMELLE N et al.: Mediterranean α-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet (1994) 343(8911):1454-1459.
  • SINGH RB, DUBNOV G, NIAZ MA et al.: Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high-risk patients (Indo-Mediterranean Diet Heart Study): a randomized single-blind trial. Lancet (2002) 360:1455-1461.
  • SPENCE JD: Nutrition and stroke prevention. Stroke (2006) 37(9):2430-2435.
  • CRITCHLEY JA, CAPEWELL S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA (2003) 290(1):86-97.
  • SACCO RL, ADAMS R, ALBERS G et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke (2006) (2):577-617.
  • BURT A, THORNLEY P, ILLINGWORTH D, WHITE P, SHAW TR, TURNER R: Stopping smoking after myocardial infarction. Lancet (1974) 1(7852):304-306.
  • JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation [See comments]. N. Engl. J. Med. (1999) 340(9):685-691.
  • TUCCI SA, HALFORD JC, HARROLD JA, KIRKHAM TC: Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem. (2006) 13(22):2669-2680.
  • CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. (2004) (4):501-508.
  • JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 6(1):56-63.
  • COLLINS R, PETO R, MCMAHON S et al.: Blood pressure, stroke and coronary artery disease. Lancet (1990) 335:827-838 (Abstract).
  • SPENCE JD: Antihypertensive drugs and prevention of atherosclerotic stroke. Stroke (1986) 17:808-810.
  • BASS MJ, MCWHINNEY IR, DONNER A: Do family physicians need medical assistants to detect and manage hypertension? CMAJ (1986) 134:1247-1255.
  • SPENCE JD: Physiologic tailoring of therapy for resistant hypertension: 20 year' experience with stimulated renin profiling. Am. J. Hypertens. (1999) 12:1077-1083.
  • BIRKETT NJ, DONNER AP, MAYNARD M: Prevalence and control of hypertension in an Ontario county. Can. Med. Assoc. J. (1985) 132(9):1019-1024.
  • SPENCE JD: Cerebral consequences of hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Edition. Laragh JH, Brenner B (Eds), Raven Press, New York (1995):741-753.
  • BARNETT HJ, TAYLOR DW, ELIASZIW M et al.: Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators [See comments]. N. Engl. J. Med. (1998) 339(20):1415-1425.
  • PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet (2001) 358:1033-1041.
  • DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995-1003.
  • SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36(6):1218-1226.
  • THE ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA (2002) 288(23):2981-2997.
  • WING LM, REID CM, RYAN P et al.: Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin. Exp. Hypertens. (1997) 19(5-6):779-791.
  • DAHLOF B, SEVER PS, POULTER NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366(9489):895-906.
  • SPENCE JD: Individualized therapy for hypertension. Hypertension (2006) 47(3):E11.
  • LARAGH JH: Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for β-blocking drugs such as propranolol. Am. J. Med. (1976) 61:797-810.
  • WALLACH L, NYARAI I, DAWSON KG: Stimulated renin: a screening test for hypertension. Ann. Intern. Med. (1975) 82:27-34.
  • SPENCE JD: Management of resistant hypertension in patients with carotid stenosis: high prevalence of renovascular hypertension. Cerebrovasc. Dis. (2000) 10:249-254.
  • SPENCE JD: Treatment options for renovascular hypertension. Expert Opin. Pharmacother. (2002) 3:411-416.
  • BIGLIERI EG, KATER CE, ARTEAGA EE: Primary aldosteronism is composed of primary adrenal hyperplasia and adenoma. J. Hypertens. (1984) 2(Suppl.):S259-S261.
  • BAKER EH, DUGGAL A, DONG Y et al.: Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. Hypertension (2002) 40:13-17.
  • SWIFT PA, MACGREGOR GA: Genetic variation in the epithelial sodium channel: a risk factor for hypertension in people of African origin. Adv. Ren. Replace Ther. (2004) 11(1):76-86.
  • TAYLOR DW, BARNETT HJ, HAYNES RB et al.: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet (1999) 353(9171):2179-2184.
  • HALKES PH, VAN GJ, KAPPELLE LJ, KOUDSTAAL PJ, ALGRA A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet (2006) 367(9523):1665-1673.
  • ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324(7329):71-86.
  • CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348(9038):1329-1339.
  • NORRIS JW, HACHINSKI VC, MYERS MG, CALLOW J, WONG T, MOORE RW: Serum cardiac enzymes in stroke. Stroke (1979) 10(5):548-553.
  • HUTCHINSON EC, ACHESON EJ: Strokes Natural History, Pathology and Surgical Treatment. London, WB Saunders Co. Ltd. (1975).
  • SAXENA R, KOUDSTAAL PJ: Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst. Rev. (2004) (2):CD000185.
  • HUMPHRIES KH, JACKEVICIUS C, GONG Y et al.: Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can. J. Cardiol. (2004) 20(9):869-876.
  • ELIASSON M, LINDAHL B, LUNDBERG V, STEGMAYR B: Diabetes and obesity in Northern Sweden: occurrence and risk factors for stroke and myocardial infarction. Scand. J. Public Health Suppl. (2003) 61:70-77.
  • SELVIN E, CORESH J, SHAHAR E, ZHANG L, STEFFES M, SHARRETT AR: Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol. (2005) 4(12):821-826.
  • DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes (1995) 44(8):968-983.
  • UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-583.
  • THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. (1995) 47(6):1703-1720.
  • THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP: Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am. J. Cardiol. (1995) 75(14):894-903.
  • STETTLER C, ALLEMANN S, JUNI P et al.: Glycemic control and macrovascular disease in Types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am. Heart J. (2006) 152(1):27-38.
  • WILCOX R, BOUSSER MG, BETTERIDGE DJ et al.: Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke (2007) 38(3):865-873.
  • EUROPEAN CAROTID SURGERY TRIALISTS' COLLABORATIVE GROUP: Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet (1998) 351:1379-1387.
  • EXECUTIVE COMMITTEE FOR THE ASYMPTOMATIC CAROTID ATHEROSCLEROSIS STUDY: Endarterectomy for asymptomatic carotid artery stenosis. J. Am. Med. Assoc. (1995) 272:1421-1428.
  • ROTHWELL PM: ACST: which subgroups will benefit most from carotid endarterectomy? Lancet (2004) 364(9440):1122-1123.
  • KRESOWIK TF, BRATZLER D, KARP HR et al.: Multistate utilization, processes, and outcomes of carotid endarterectomy. J. Vasc. Surg. (2001) 33(2):227-234.
  • PERRY JR, SZALAI JP, NORRIS JW; FOR THE CANADIAN STROKE CONSORTIUM: Consensus against carotid surgery and screening for asymptomatic stenosis. Arch. Neurol. (1997) 54:25-28.
  • SPENCE JD, TAMAYO A, LOWNIE SP, NG WP, FERGUSON GG: Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke (2005) 36(11):2373-2378.
  • MARKUS HS, MACKINNON A: Asymptomatic embolization detected by doppler ultrasound predicts stroke risk in symptomatic carotid artery stenosis. Stroke (2005) 36:971-975.
  • HACHINSKI V, GRAFFAGNINO C, BEAUDRY M et al.: Lipids and stroke: a paradox resolved. Arch. Neurol. (1996) 53(4):303-308.
  • AMARENCO P, LAVALLEE P, TOUBOUL PJ: Stroke prevention, blood cholesterol, and statins. Lancet Neurol. (2004) 3(5):271-278.
  • AMARENCO P, BOGOUSSLAVSKY J, CALLAHAN A III et al.: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355(6):549-559.
  • BØNAA KH, NJØLSTAD I, UELAND PM et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. (2006) 354(15):1578-1588.
  • GRAHAM IM, DALY L, REFSUM H, ROBINSON K et al.: Plasma homocysteine as a risk factor for vascular disease. JAMA (1997) 277:1775-1781.
  • NYGÅRD O, NORDREHAUG JE, REFSUM H, UELAND PM, FARSTAD M, VOLLSET SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. (1997) 337:230-236.
  • LOFFREDO L, VIOLI F, FIMOGNARI FL et al.: The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica (2005) 90(9):1205-1211.
  • POLI D, ANTONUCCI E, CECCHI E et al.: Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke (2005) 36(10):2159-2163.
  • LONN E, YUSUF S, ARNOLD MJ et al.: Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. (2006) 354(15):1567-1577.
  • REFSUM H, SMITH AD: Homocysteine, B vitamins, and cardiovascular disease. N. Engl. J. Med. (2006) 355(2):207-211.
  • NAYLOR AR, BOLIA A, ABBOTT RJ et al.: Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J. Vasc. Surg. (1998) 28(2):326-334.
  • MAS JL, CHATELLIER G, BEYSSEN B: Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial. Stroke (2004) 35(1):E18-E20.
  • ALBERTS MJ; FOR THE PUBLICATIONS COMMITTEE OF THE WALLSTENT: Results of a multicenter prospective randomized trial of carotid artery stenting vs carotid endarterectomy. Stroke (2001) 32:325 (Abstract).
  • HALLIDAY A, MANSFIELD A, MARRO J et al.: Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet (2004) 363(9420):1491-1502.
  • CAVATAS INVSTIGATORS: Endovascular versus surgical treatment in patients with carotid stenosis in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): a randomised trial. Lancet (2001) 357(9270):1729-1737.
  • YADAV JS, WHOLEY MH, KUNTZ RE et al.: Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. (2004) 351(15):1493-1501.
  • HOBSON RW: CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status. Semin. Vasc. Surg. (2000) 13(2):139-143.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.